ERBB2 and neoplasm: Additional studies have investigated the use of a nanosized immunoliposome-based anti-HER-2 siRNA delivery complex to preferentially target tumour cells, where efficiency of the complex was improved by the inclusion of a pH-sensitive histidine-lysine peptide [123].